Compare REBN & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REBN | CLGN |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Restaurants | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.2M | 6.0M |
| IPO Year | 2017 | 2015 |
| Metric | REBN | CLGN |
|---|---|---|
| Price | $2.17 | $0.41 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | 35.4K | ★ 40.0K |
| Earning Date | 04-22-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,094,628.00 | N/A |
| Revenue This Year | N/A | $240.45 |
| Revenue Next Year | N/A | $38.03 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 36.54 | N/A |
| 52 Week Low | $1.36 | $0.27 |
| 52 Week High | $3.40 | $4.98 |
| Indicator | REBN | CLGN |
|---|---|---|
| Relative Strength Index (RSI) | 45.93 | 48.44 |
| Support Level | $2.03 | $0.35 |
| Resistance Level | $2.57 | $0.45 |
| Average True Range (ATR) | 0.15 | 0.04 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 34.50 | 61.46 |
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is a company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in two reportable segments: Reborn Coffee, which includes both the wholesale and retail sales of coffee, water, and other beverages, and Reborn Logistics, which provides freight forwarding services.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.